View more in
Cancer

Phase 3 Trial of Sugemalimab in Stage III NSCLC Meets Primary End Point

cancernetwork.com
 2021-06-03

Cover picture for the articleBased on positive phase 3 results, a new drug application for sugemalimab to treat patients with locally advanced or unresectable stage III non–small cell lung cancer will likely be submitted to the FDA. The phase 3 GEMSTONE-301 trial (NCT03728556) of the anti–PD-L1 monoclonal antibody sugemalimab met its primary end point...

www.cancernetwork.com

Comments / 0

Comments / 0